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1. Introduction 
Acute myeloid leukemia (AML) with t(8;21) (q22;q22)translocation (t(8;21)AML) is one of 
the major disease group of AML, accounting for 7 to 8% of adult AML, with most classified 
as M2 by FAB classification (Ferrara & Del Vecchio, 2002). In the reports from Western 
countries to date, it has been reported that the survival rate of patients with t8;21-associated 
AML can be improved by employing consolidation therapy with high-dose cytarabine, 
which has a good remission and survival rate compared to other AML (Byrd et al, 1999) 
(Grimwade et al, 1998). 
According to recent research by the Group B Study of Cancer and Leukemia, it has been 
suggested that the treatment outcome of t(8;21)AML may differ depending on race 
(Marcucci et al, 2005). This indicates that the knowledge from past research in Western 
countries cannot necessarily be directly transferred to Japanese patients, but the reality is 
that research related to the clinical features of Japanese t(8;21)AML is very limited. Of these 
publications, the best summarized report is the analysis of patients participating in a clinical 
study of Japan adult leukemia study group (JALSG) by Nishii et al. in 2003 (Nishii et al, 
2003). This report reveals that the overall 5-year survival rate was 52%. However, this report 
mainly focuses on the additional chromosome abnormality of t(8;21)AML. Many clinicians 
felt the need for new research in order to clarify the clinical features of t(8;21)AML in 
Japanese patients, such as prognosis and treatment outcomes. 
The research group of the authors appealed to clinicians and researchers aware of such 
issues, arranged participation of institutes for which approval was obtained, and conducted 
a retrospective study with the purpose of clarifying clinical features in Japanese patients. 
(Narimatsu et al, 2008b) This article will compare reports from Western countries to date 
focused on the outcome, and explain the clinical characteristics of t(8;21)AML in Japanese 
patients. 
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2. Japanese t(8;21)AML patients have a favorable survival rate 
The authors retrospectively investigated clinical features of 46 adult t(8;21)AML patients 
newly diagnosed at facilities participating in the research from 2000 to 2005 as the subjects 
(Narimatsu et al, 2008b). The comparison of its outcome with prior researches (Appelbaum 
et al, 2006; Marcucci et al, 2005; Nguyen et al, 2002; Schlenk et al, 2004) is shown in Table 1. 
First off, the 3-year overall survival rate of Japanese t(8;21)AML patients reported by the 
authors was 70%. A definite conclusion cannot be drawn due to the short follow-up period, 
but close to 70% were estimated to have a 5-year survival rate. This is a good number 
compared to past reports from Western countries, in which 5-year survival rate ranged from 
45% to 59% (Appelbaum et al, 2006; Marcucci et al, 2005; Nguyen et al, 2002). On the other 
hand, age, which is the greatest risk factor for the survival of leukemia patients, was older in 
reports from Japan compared to reports from Western countries. Moreover, white blood cell 
counts and blood platelet counts at the initial visit, which are also believed to be risk factors, 
were the same in reports from Japan and reports from Western countries. From these 
comparisons, it was suggested that the prognosis of Japanese t(8;21)AML patients was better 
than the prognosis of Westerners, and a possibility that racial differences may be involved 
as its cause, rather than the inclusion of background factors such as age and white blood cell 
count at initial visit, was suggested. 
The authors also compared the survival rate of t(8;21)AML patients and leukemia patients 
that were diagnosed in each institute at the same time as AML(M2) having no t(8;21) 
abnormality(Narimatsu et al, 2008b). As a result, the overall survival rate of t(8;21)AML 
patients was significantly better than AML(M2) patients without t(8;21) (70% vs. 43% for 3-
year overall survival rate). However, the age of AML(M2) patients without t(8;21) was 
significantly higher compared to t(8;21)AML, so the overall survival rate was compared by 
limiting patients to those 60-years old or younger. As a result, the 3-year survival rate was 
71%(n=35, patients with t(8;21)) and 58% (n=49, patients without t(8;21)), respectively, 
narrowing the difference, with no significant difference observed between the two groups. 
Furthermore, when prognosis factor analysis was conducted with all these patients as 
subjects, the presence of t(8;21) was not a significant prognosis factor(Narimatsu et al, 
2008b). These results suggest that young age is the main reason for good prognosis in 
t(8;21)AML patients, which is very interesting. 
3. Prognosis factor 
It was revealed from the investigation of Japanese t(8;21)AML patients by the authors that 
the older the age, the higher the white blood cell count at the initial visit, and the worse 
the survival rate. This, as shown in Table 1, can be said to be almost the same as the 
outcome of the research in Western countries. However, chromosome abnormalities 
additionally occurring in t(8;21), such as the deficiency of a sex chromosome and/or 
chromosome-9-abnormality that have been pointed out in much prior research, was not 
an apparent prognosis factor. This is the same finding as the research by Nishii et al. from 
JALSG, and there is a possibility that this may be the difference with Western patients 
(Nishii et al, 2003). 
Moreover, although not included in the research by the authors, the report by Nishi et al. 
showed that the prognosis of patients with an addition of trisomy 4 is extremely poor, and  
www.intechopen.com
 
Clinical Characteristics of Acute Myeloid Leukemia with t(8;21) in Japan and Western Countries 
 
213 
 
Table 1. Research on the recent clinical characteristics of t(8;l21)AML within Japan and other 
overseas countries 
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clinicians should make note of this fact. In one of those patients, Nishii et al showed c-kit 
mutation of the leukemia cells (Langabeer et al, 2003). KIT mutation may related to this 
unfavorable outcome, which needs to be clarified in further large study. 
4. Is high dose cytarabine therapy effective? 
It has been reported by prior research in Western countries that high dose cytarabine 
therapy can improve the treatment outcome of t(8;21)AML patients(Byrd et al, 1999; Ferrara 
& Del Vecchio, 2002). The authors also investigated whether or not the same can be said of 
Japanese patients. As a result, the survival rate of 14 patients who underwent consolidation 
therapy with a standard dose of cytarabine and that of 19 patients who underwent 
consolidation therapy with a high-dose cytarabine was approximately the same. However, 
numbers of those patients are small and the consolidation regimen of these patients covered 
various grounds, and it is difficult to discuss the efficacy of high dose cytarabine therapy 
from this result. Increased fatal side effects such as infectious diseases are a concern with 
high dose cytarabine therapy, but from this result, it is suggested that high-dose cytarabine 
can also be conducted in Japanese patients. 
Recently, the outcome of a randomized controlled trial of consolidation therapy with high 
dose cytarabine therapy and multi-drug therapy was reported by a JALSG group. 
According to their report, although high dose cytarabine therapy shows a better outcome for 
disease free survival and overall survival compared to multi-drug therapy at a standard 
dosage, the results did not have any apparent significant differences (Miyawaki et al, 2011). 
This differs from the research report accounting for the usefulness of high-dose cytarabine 
in Western countries represented by the research by Bloomfield et al (Bloomfield et al, 1998). 
On the other hand, documented severe infections are common in high-dose cytarabine 
groups. This difference is presumed to be related to the difference in the incidence of 
tyrosine kinase such as KIT, etc., which is believed to affect the prognosis, and there is a 
need to clarify this in future research. 
Taking the above outcomes into account, at this point, the decision regarding whether or not 
to apply high-dose cytarabine to Japanese t(8;21)AML patients must be determined by the 
on-site clinician. 
5. The significance of measuring minimal residual disease 
RUNX1 (AML1)/MTG8 (ETO) transcript occurs as a result of t(8;21)(q22;q22) 
translocation. The minimal residual disease can be evaluated by qualitatively and 
quantitatively measuring this transcript by the PCR method. In some small scale research 
from Western countries, it has been reported that patients with a high risk for relapse can 
be determined by evaluating minimal residual disease. (Krauter et al, 2003; Leroy et al, 
2005; Perea et al, 2006; Tobal et al, 2000) (Weisser et al, 2007) Therefore, in the same way, 
the authors also investigated the clinical significance of minimal residual disease in 
Japanese t(8;21)AML patients by collecting the outcome of RUNX1/MTG8 quantitative 
tests from the clinical records of 26 t(8;21)AML patients that reached complete remission 
(Narimatsu et al, 2008a). As a result, between the group that reached less than 1,000 copies 
of RUNX1/MTG8 transcript when remission was reached (n=13) and the group that did 
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not (n=7), the relapse-free survival rate was better in the latter group. This shows that in 
contrast to reports from Western countries, in Japanese patients, the number of copies of 
RUNX1/MTG8 transcript when remission is reached does not necessarily reflect 
prognosis; however, number of study patients are small and it is difficult to make a 
definite conclusion. On the other hand, relapse is expected in patients in whom 
RUNX1/MTG8 transcript increased during the remission period, and monitoring 
RUNX1/MTG8 transcript during the remission period was suggested to have significance 
in terms of early prediction of relapse. 
6. Conclusion - Issues to be solved in the future 
The motivation for the group of the authors to initiate research was the hypothesis of the 
authors, “Reports on t(8;21)AML from Western countries do not match the feeling of actual 
clinical practice.” Outcomes actually investigated also suggested a possibility of clinical 
features differing between Western t(8;21)AML patients and Japanese t(8;21)AML patients. 
It will be necessary to conduct large-scale research and/or a prospective study on Japanese 
patients as well in the future, in order to create evidence for Japanese t(8;21)AML patients. 
The following are listed in concrete terms. 
1. It is necessary to conduct a large-scale retrospective study to compare the survival rate 
of t(8;21)AML to that of AML with other chromosome abnormalities or AML without 
any. Furthermore, it is necessary to clarify if t(8;21) translocation is a significant 
prognosis factor of AML (as in the research by the authors, if the young age of 
t(8;21)AML patients is responsible for good prognosis). 
2. It is necessary to clarify the molecular biological characteristics of t(8;21)AML in 
Japanese patients. Particularly, investigation into whether or not the frequency of 
tyrosine kinase mutation, N-Ras mutation,,which are believed to have an effect on 
prognosis, is different between t(8;21)AML in Japan and Western countries, should be 
useful. 
3. It is also necessary to reinvestigate the clinical significance of minimal residual disease 
by research designed so as to unify when specimens were retrieved and the method of 
examination with patients treated, using the same regimen as the subject. 
The clarification of clinical features of t(8;21)AML in Japanese and Western patients and 
the establishment of optimum therapy customized for every ethnicity is hoped for in the 
near future. 
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